Asset
ADALIMUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03849404 | phase3 | completed | 2019-02-20 | 2019-12-23 | Alvotech Swiss AG | Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis |
| NCT03983876 | phase1 | completed | 2019-07-01 | 2019-12-03 | Alvotech Swiss AG | PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) |
| NCT03849313 | phase1 | completed | 2019-03-20 | 2020-02-17 | Alvotech Swiss AG | Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) |
FDA applications (0)
This company has no applications containing this asset.